Evidence map›Paper›PMID 18577710›Full record

ArticleBlood2008

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Laura Z Rassenti, Sonia Jain, Michael J Keating, William G Wierda, Michael R Grever, John C Byrd, Neil E Kay, Jennifer R Brown, John G Gribben, Donna S Neuberg and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 3 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 3 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Laura Z RassentiThe Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA.
Sonia Jain
Michael J Keating
William G Wierda
Michael R Grever
John C Byrd
Neil E Kay
Jennifer R Brown
John G Gribben
Donna S Neuberg
Feng He
Andrew W Greaves
Kanti R Rai
Thomas J Kipps
University of California, San Diego · USDana-Farber Cancer Institute · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe University of Texas MD Anderson Cancer Center · USLong Island Jewish Medical Center · USMayo Clinic in Arizona · US

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
Genetic Alterations in Families with Multiple LymphomasK23CA115682 · NCI · DANA-FARBER CANCER INSTITUTE · PI BROWN, JENNIFER R · 2005 to 2009
$754k
NCI NIH HHS K23 CA115682NCI NIH HHS P01 CA081534NCI NIH HHS P01-CA81534
6 · The paper itself

Abstract

Leukemia-cell expression of ZAP-70, CD38, or unmutated immunoglobulin heavy chain variable region genes (U-IGHV) each is associated with aggressive disease in patients with chronic lymphocytic leukemia (CLL). To assess the relative strength of each marker, we defined thresholds for designating a case as positive for CD38 or ZAP-70 in a test cohort of 307 patients and used these data-defined criteria to stratify patients in an independent cohort of 705 patients. Multivariable analysis revealed that ZAP-70 was the strongest risk factor. Knowledge of the IGHV mutation status or CD38 did not improve our ability to predict the time to first treatment except for ZAP-70-negative cases, which could be segregated into 2 groups of intermediate-risk or low-risk disease based on whether they expressed unmutated or mutated IGHV. ZAP-70 maintained its high relative prognostic value for the subset of patients with early-stage, asymptomatic disease, including patients evaluated within 1 year of diagnosis. Although it is premature to recommend therapy based on these risk factors, patients with ZAP-70-positive CLL cells should be monitored closely for disease progression as they have a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3 years.

Indexed as

Genes, Immunoglobulin Heavy ChainMutationADP-ribosyl Cyclase 1AdultAgedAged, 80 and overBiomarkers, TumorCohort StudiesFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMembrane GlycoproteinsMiddle AgedPrognosisRisk FactorsADP-ribosyl Cyclase 1Biomarkers, TumorCD38 protein, humanMembrane GlycoproteinsZAP-70 Protein-Tyrosine Kinase

Identifiers

PMID18577710
PMCPMC2518894
OpenAlexW1979918288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.